AB Science’s initial phase one data (update) on the AB8939 program in AML disclosed

Image Credit: americanbuilt. app

Announcement 

AB Science, a leading French pharmaceutical company, aims to establish novel drugs to offer unmet medical needs for conditions like neurology, inflammation, and oncology has delivered initial phase 1 data for the merger of AB8939 with relapsed acute myeloid leukaemia or venetoclax for the treatment of refractory conditions. The presentation for website access is available on the company’s site under the press release section: http://www.ab-science.com/news-and-media/press-releases/.

Key factors of the presentation

The AB8939 detected activity in MECOM with the length of OS benefit in monotherapy. Under combination therapy, it is noted that there’s a powerful rationale to merge AB8939 with venetoclax. As the merger treatment is well tolerated in both molecules, it consists of complementary and unique focuses in cancer cells. Including the partial response rate is 100% (3/3), and the disease control rate is 100% (3/3), involving complete remission in one patient. These results were shown after the initial stage of (14 days) treatment for receiving third-or fourth-line treatment in patients, and two in existing patients progressed on venetoclax in merger with other chemotherapies.

The last step in the presentation is to officially finish phase 1 in the merger and launch the extensive study in almost 15 AML patients suitable for venetoclax plus AB8939 at the right dose.

Healthcare leaders’ statements

The MD, associate professor and co-lead of the section of developmental therapeutics, department of leukaemia, MD Anderson Cancer Centre, Nicholas J. Short said, “The early data suggested that AB8939, the combination and/or monotherapy, could have a prominent activity in the accelerated risk subtypes of AML. If a slight similarity is found in safety and response rate during trial extension, then the AB8939 will be considered well-positioned for development in unfavourable risk AML in salvage and frontline settings.”

The PharmD, PhD, Professor emeritus, former director and cofounder of the phd program in oncology at institute gustave Roussy, Paris-Saclay University, Christian Auclair said, “The dual property of AB8939 focusing cancer stem cells and cancer cells proves AB8939 an ideal molecule for the high-risk leukaemia treatment by mitigating the frequency of relapses. It is an excellent tolerated molecule featuring less bone marrow toxicity.”

The MD, president of the scientific committee of AB science and member of the Académie des Sciences in France, Professor Olivier Hermine, said, “Because the amalgamation of venetoclax and AB8939 shows less haematological toxicity, it has become essential as it enables patients to gain various cycles of treatment and live a satisfactory quality of life.”